A Single-blinded Multicenter Randomized Study Comparing Intubating Conditions After Either Rocuronium 0.6 mg/kg or Remifentanil 2 µg/kg in Elderly Patients
Overview
- Phase
- Phase 4
- Intervention
- Rocuronium 0.6 mg/kg
- Conditions
- Neuromuscular Blockade
- Sponsor
- Rigshospitalet, Denmark
- Enrollment
- 78
- Locations
- 2
- Primary Endpoint
- Evaluation of intubating conditions ad modum Fuchs-Buder et al
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The number of elderly patients above 80 years is increasing and a large proportion of these patients will require surgery and anesthesia.
During anesthesia neuromuscular blocking agents (NMBA) are administered to facilitate intubating conditions and reduce the trauma to the larynx and vocal cords. There is a risk of residual neuromuscular block when using NMBAs like rocuronium.
Remifentanil is a fentanyl analogue commonly used for induction since it also facilitates intubation. There is no risk of residual neuromuscular block, nonetheless circulatory side effects have been seen.
It is unknown which is superior concerning intubating conditions in elderly patients. Therefore, the aim of this study is to determine the effect on intubating conditions and laryngeal morbidity after either rocuronium 0.6 mg/kg or remifentanil 2 µg/kg in patients with age ≥ 80 years. The hypothesis of this study is that rocuronium 0.6 mg/kg provides a higher proportion with excellent intubating conditions compared to remifentanil 2 µg/kg.
Detailed Description
The number of elderly patients (\>80 years) is increasing and a large proportion of these patients will require surgery and anesthesia within the next decades. Elderly patients are at higher risk of major morbidity and mortality and are characterized by a reduction in cardiac output, liver function and renal function. These physiological changes influence pharmacodynamics and pharmacokinetics of drugs administered during anesthesia. During anesthesia neuromuscular blocking agents (NMBA) are administered to facilitate intubating conditions and reduce the trauma to the larynx and vocal cords. Studies suggests that avoidance of neuromuscular blocking agents (NMBAs) increases the risk of difficult tracheal intubation and leads to impaired intubating conditions with direct laryngoscopy. Furthermore, avoidance of NMBA significantly increases the risk of upper airway discomfort or injury. Even low doses of rocuronium may be associated with a significant improvement of intubating conditions. Remifentanil is a fentanyl analogue commonly used for induction since it also facilitates intubation. There is no risk of residual neuromuscular block, nonetheless circulatory side effects have been seen. The possible benefit in this trial is to investigate whether rocuronium 0.6 mg/kg or remifentanil 2 µg/kg provides best intubating conditions in the elderly. This may result in different intubating difficulty scores between the two groups of elderly patients. The results may help to detect the optimal method for intubation of the trachea in elderly patients. The aim of this study is to determine the effect on intubating conditions and laryngeal morbidity after either rocuronium 0.6 mg/kg or remifentanil 2 µg/kg in patients with age ≥ 80 years. The hypothesis of this study is that rocuronium 0.6 mg/kg provides a higher proportion with excellent intubating conditions compared to remifentanil 2 µg/kg.
Investigators
Matias Vested
Principal Investigator, Anesthesiologist
Rigshospitalet, Denmark
Eligibility Criteria
Inclusion Criteria
- •Scheduled for elective operations (expected duration of anesthesia \> 1 hour) under general anesthesia with intubation
- •American Society of Anesthesiologists physical status classification (ASA) I to III
- •Informed consent (see appendix 1)
- •Read and understand Danish
Exclusion Criteria
- •Neuromuscular disease
- •Known allergy to rocuronium, remifentanil or sugammadex
- •Rapid sequence induction
Arms & Interventions
Group receiving rocuronium at induction
Rocuronium 0,6 mg/kg at induction
Intervention: Rocuronium 0.6 mg/kg
Group receiving remifentanil at induction
Remifentanil 2 μg/kg at induction
Intervention: Remifentanil 2 µg/kg
Outcomes
Primary Outcomes
Evaluation of intubating conditions ad modum Fuchs-Buder et al
Time Frame: 2 minutes after start of administration of trial medication
Occurrence of excellent intubating conditions 2 minutes after start of administration of 0.6 mg/kg rocuronium or 2 µg/kg remifentanil, scored according to Fuchs-Buder et al. The intubating conditions will be classified as excellent if all qualities are excellent, good if all qualities are either excellent or good and poor if the presence of a single quality is listed as poor.
Secondary Outcomes
- Subjective side effects of laryngoscopy(24 hours postoperatively and 3 days postoperatively)
- Dose of ephedrine or dose of metaoxedrine administered(From induction until the patient is ready to be positioned for surgery, ranging from 5 minutes up to 1 hour.)
- Intubating conditions according to IDS(2 minutes after start of administration of trial medication)